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Abstract: AMP activated protein kinase (AMPK) is a key regulator of cellular metabolism. AMPK activity is modulated 
in part by binding of AMP to the -subunit of the kinase, which increases the activity of the catalytic -subunit. Because 
increased AMPK activity in the liver and in skeletal muscle leads to increased fatty acid oxidation and decreased choles-
terol and fatty acid biosynthesis, activators of AMPK are being sought for treatment of type-2 diabetes and other meta-
bolic disorders. The unique mechanism of AMPK activation offers an opportunity to develop small molecules that directly 
upregulate AMPK activity, and there exists a need for simplified methods to identify and characterize small-molecules 
that show isoform-specific effects on AMPK. We have developed a suite of fluorescence-based assays to identify and 
characterize such compounds, and have used these to characterize and compare activity of recombinant AMPK 111 and 
211 isoforms in response to small molecule activators and inhibitors. 
INTRODUCTION  
  AMP-activated protein kinase (AMPK) plays a central 
role in regulating metabolic activity by downregulating 
ATP-consuming processes and upregulating catabolism in 
response to environmental stresses that decrease the cellular 
[ATP]:[AMP] ratio. Upon activation, AMPK phosphorylates 
and inactivates acetyl CoA carboxylase (ACC, involved in 
fatty acid biosynthesis), HMG-CoA reductase (a key regula-
tor of cholesterol synthesis and the target of the statin class 
of drugs) [1], as well as glycogen synthase [2]. AMPK is a 
heterotrimeric complex consisting of , , and  subunits [3, 
4], and is directly regulated by at least three processes: acti-
vation through phosphorylation of Thr-172 in the activation 
loop of the catalytic  subunit by LKB1 [5-9] or CaMKK 
or  [10, 11], deactivation via dephosphorylation at this site 
by PP2 [12], and allosteric activation via AMP [13]. 
  AMPK is broadly expressed in a variety of tissues, with 
different isoforms being dominantly expressed in different 
tissues. The trimeric complex consists of ,  , and  
subunits, with two isoforms identified for each of the  and 
 subunits, and three identified for the  subunit, giving rise 
to a possibility of twelve isoforms of AMPK. In liver, the 1 
and 2 subunits are present in approximately equal amounts, 
with the 1 and 1 being the predominant forms of their re-
spective subunits [14]. In contrast, in heart and in skeletal 
muscle the 2 form predominates over the 1 form by a 
greater than a 2:1 ratio, and the 2 subunit is predominant 
over the 1 form in these tissues as well [15].  
  Therapeutic targeting of AMPK activation has been 
shown to have positive results in models of diabetes. The 
small molecule drug metformin has been used for approxi- 
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mately 50 years in the treatment of type 2 diabetes, and func-
tions by indirectly promoting AMPK phosphorylation and 
activation [16]. Another small molecule, AICAR (5-
aminoimidazole-4-carbozamide riboside), has proven to be a 
useful tool for pharmacologically activating AMPK without 
perturbing the cellular [ATP]:[AMP] ratio. AICAR is taken 
up into cells via  the adenosine transport system and then 
phosphorylated to form AICAR monophosphate, or ZMP 
[17], which activates AMPK by binding to the allosteric 
AMP-binding site. Recently, the results of a highly miniatur-
ized radiometric assay were reported, in which of a library of 
over 700,000 compounds was screened for AMPK activators 
or inhibitors [18], and optimization of hits led to a thieno-
pyridone-based small molecule (A-769662) that activated 
rat-liver or recombinant AMPK (111) with an EC50 of 
approximately 800 nM, and showed positive effects in the 
treatment of diabetic ob/ob mice [19]. Interestingly, this 
compound was able to increase AMPK activity in vitro in the 
presence of saturating amounts of AMP, suggesting the pos-
sibility of multiple allosteric sites that can be exploited to 
develop compounds that activate AMPK. Additionally, 
AMPK activation has emerged as a therapeutic target for 
atherosclerosis and cancer [20]. 
  In addition to therapeutic interest in AMPK activation, 
there is evidence that either direct inhibition [21] or a leptin-
induced decrease [22, 23] in AMPK activity in the hypo-
thalamus can reduce food intake and body weight. Com-
pound C, a pyrazo[1,5-a]pyrimidine compound that inhibits 
AMPK was discovered in a high-throughput screen [16] and 
subsequently shown to decrease food intake in mice [21]. 
Expression of a dominant negative form of AMPK in mouse 
hypothalamus was shown to reduce both food intake and 
weight gain, with opposite results seen when a constitutively 
active form of AMPK was expressed [22]. 
  Because of the key role that AMPK plays in maintaining 
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exist in different tissues, there is a need for simple, homoge-
nous, non-radiometric methods to identify and characterize 
small-molecule modulators of AMPK activity. To address 
this need, we have developed a suite of assays (Fig. 1) for 
different stages of the discovery process. We have developed 
a time resolved Förster resonance energy transfer (TR-
FRET) assay that is well suited to HTS applications, due to 
its inherent resistance to common forms of assay interference 
such as colored, fluorescent, or precipitated compounds [24]. 
Further, we have developed secondary assays that provide a 
response that is directly proportional to the amount of prod-
uct formed, and are therefore well suited to detailed mecha-
nistic studies (or hit-confirmation) of small-molecule modu-
lators of AMPK activity. The first of these formats is a 
FRET-based format in which a peptide substrate for AMPK 
is labeled on its termini with a coumarin / fluorescein FRET 
pair. After the kinase reaction, a site-specific protease is 
added that preferentially cleaves non-phosphorylated sub-
strate, thereby decreasing the FRET signal that remains in-
tact in the non-cleaved, phosphorylated product [25]. In this 
manner, changes in FRET can be directly correlated to sub-
strate phosphorylation. The second format is based upon the 
principal of chelate-enhanced fluorescence (CHEF), in which 
phosphorylation of a serine, threonine, or tyrosine residue 
causes phosphate-dependent chelation of magnesium be-
tween the phosphate group and a non-natural, fluorogenic 
amino acid (Sox), that has been incorporated into the peptide 
sequence and that becomes fluorescent upon this chelating 
event [26]. The FRET-based assay format provides a con-
venient method for automated compound profiling, and the 
CHEF-based assay provides the ability to directly monitor 
purified AMPK activity in real-time. 
MATERIALS AND METHODS  
General Reagents 
  AMP, ZMP (5-Aminoimidazole-4-carboxamide-1--D-
ribofuranosyl 5-monophos-phate), APR (adenosine 5- mo-
nophosphoramidate) and ATMP (adenosine 5-O-
thiomonophosphate) were from Sigma-Aldrich (St Louis, 
MO). Compound C (6-[4-(2-Piperidin-1-yl-ethoxy)-
phenyl)]-3-pyridin-4-yl-pyrrazolo [1,5-a] - pyrimidine) was 
from EMD Chemicals Inc (San Diego, CA). TR-FRET based 
assay reagents (commercialized under the LanthaScreen™ 
TR-FRET trade name) and FRET-based assay reagents 
(commercialized under the Z’-LYTE™ trade name) and 
CAMKK1 were from Invitrogen Discovery Sciences (Madi-
son, WI). CHEF-based assay reagents (commercialized un-
der the Omnia™ trade name) were from Biosource (Hopkin-
ton, MA). SAMS peptide substrate was from Upstate. 
Cloning, Expression, and Purification of AMPK 111 
and 211. 
 Genes  for  the  1 (accession # NP_006242.4),  2 
(NP_006243.2), and 1 (NP_006244.2) subunits were fused 
to the 3’ end of the GST gene found in pDEST20 via stan-
dard GATEWAY subcloning methods. The 1 gene 
(NP_002724.1) was subcloned in pDEST10 in order to cre-
ate a vector that would express a protein with an N-terminal 
His tag. Bacmid DNA was derived from all four vectors, and 
used to transfect insect cells. AMPK 111 and 211 were 
expressed in Sf9 insect cells using an MOI of 1 for each 
subunit. The cells were harvested 72 hours post infection and 
the cell paste was stored at -80°C until needed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Schematic of fluorescent assay formats used to character-
ize AMPK activators of inhibitors. (A) The TR-FRET format de-
tects association between fluorescein labeled, phosphorylated pep-
tide and a terbium-labeled phosphospecific antibody. (B) The 
FRET-based format uses a peptide substrate terminally labeled with 
a coumarin-fluorescein FRET pair and measures the amount of 
phosphorylated product due to a decrease in sensitivity of the phos-
phorylated peptide to proteolysis. (C) The CHEF-based format uses 
a peptide substrate that incorporates the non-natural, fluorogenic 
Sox residue. Upon phosphorylation of a proximal serine, threonine, 
or tyrosine residue, the Sox moiety forms a Mg
2+ mediated bridge 
between the Sox residue and the phosphate group and becomes 
fluorescent.  
  Both AMPK isoforms were purified similarly, and all 
steps were performed on ice or at 4˚C unless otherwise 
stated. Cell paste was suspended in lysis buffer (20 mM Tris 
pH 8.0, 1% Triton X-100, 1 mM Na3VO4, 25 mM -
glycerophosphate, 1 mM PMSF, 5 mM benzamidine, 10 
μg/mL leupeptin, 10 μM E-64, 2 mM EDTA, and 2 mM 
DTT), mixed with a hand-held homogenizer, and then clari-
fied by centrifugation. The clarified lysate was then purified 
on glutathione sepharose 4B, and fractions containing sig-
nificant amounts of AMPK as determined by SDS-PAGE 
were pooled and passed over a Superdex 200 column. Frac-
tions were collected and pooled based on purity as assessed 
by SDS-PAGE and by activity as analyzed by a radiometric 
activity assay using SAMS peptide. AMPK was then con-
centrated to 0.3 mg/mL, and activated by incubation at room 
temperature for 2 hours with his-tagged CAMKK1 (0.1 mg 
per mg of AMPK), 1 mM ATP, 10 mM MgCl2, 10 μg/mL 
calmodulin, and 0.5 mM CaCl2, followed by further purifica-
tion on glutathione sepharose 4B to remove CAMKK1. The 
purified enzyme was dialyzed into storage buffer (50 mM 
Tris pH 7.5, 50% glycerol, 150 mM NaCl, 0.02% Triton X-
100, 0.5 mM EDTA, and 2 mM DTT) and stored at -80˚C 
until use.  
Radiometric Assays 
  Kinase reactions were performed at room temperature in 
50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, and 
1 mM EGTA in a 30 μL assay volume in 96-well plates. For 
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the inhibition experiments, a 2-fold dilution series of inhibi-
tor stock solutions was first prepared in 100% DMSO at 100-
fold concentration of inhibitor to be used in the assay. Prior 
to the assay, 4 μL of each inhibitor concentration was further 
diluted to 100 μL in assay buffer to prepare a working stock 
of inhibitor in 4% DMSO at 4-fold the final assay concentra-
tion. For the activation experiments, activators were prepared 
in 100% H2O at 4-fold the concentration to be tested in the 
assay. Assays were performed as follows: 7.5 μL of the in-
hibitor or activator working stock was added to a 17.5 μL 
solution of assay buffer, substrate and [
32P]-ATP (0.5 
μCi/well), followed by 5 μL of enzyme to start the assay. All 
assays were performed in triplicate. The final concentration 
of SAMS peptide substrate in the reaction was 200 μM. 
AMPK 111 was used at 334 ng/mL (1.8 nM) in the inhibi-
tion experiments and 83.3 ng/mL (0.44 nM) in the activation 
experiments, at an ATP concentration of 35 μM. AMPK 
211 was used at 1670 ng/mL (8.9 nM) in the inhibition 
experiments and 267 ng/mL (1.4 nM) in the activation ex-
periments, at an ATP concentration of 65 μM. After 10 min-
utes, 20 μL of the reaction was spotted onto a p81 filter. The 
filters were washed three times in 0.5% phosphoric acid, and 
twice in distilled water before being counted in Beckman 
Coulter Ready Safe liquid scintillation cocktail using a 
Beckman Coulter LS6500 Multipurpose Scintillation 
Counter. Scintillation Counter output (cpm) was used to cal-
culate specific activity (nmole / (min•mg)). 
Time-Resolved FRET (TR-FRET) Activity Assays 
  Kinase reactions were performed in a 10 μL assay vol-
ume at room temperature in 384-well low volume plates 
(Corning model 3676) using the same assay buffer as the 
radiometric assay. Activators and inhibitors were prepared as 
described for the radiometric assay. Assays were performed 
as follows: 2.5 μL of the inhibitor or activator working stock 
was added to a 5 μL solution of kinase and substrate, fol-
lowed by 2.5 μL of ATP to start the assay. Assays were per-
formed in quadruplicate. The final concentration of fluo-
rescein-labeled CREBtide peptide substrate (derived from 
residues 123-136 of CREB protein) in the reaction was 400 
nM. AMPK 111 was used at 600 ng/mL (3.1 nM) in the 
inhibition experiments and 200 ng/mL (1.1 nM) in the acti-
vation experiments, at an ATP concentration of 50 μM. 
AMPK 211 was used at 5 μg/mL (26.5 nM) in the inhibi-
tion experiments and 600 ng/mL (3.2 nM) in the activation 
experiments, at an ATP concentration of 150 μM. After one 
hour, a 10 μL solution of EDTA and terbium labeled phos-
pho-specific antibody in 20 mM Tris, pH 7.5 and 0.01% NP-
40 was added to a final well volume of 20 μL, a final anti-
body concentration of 1 nM, and a final EDTA concentration 
of 10 mM. After a 30 minute incubation at room temperature 
the assay plate was read on a BMG Pherastar plate reader 
using the LanthaScreen™ filter module. The TR-FRET ratio 
was calculated as the intensity of the acceptor signal divided 
by the intensity of the donor signal. 
FRET-based Kinase Activity Assays 
  Kinase reactions were performed in a 10 μL assay vol-
ume at room temperature in 384-well low volume plates 
(Corning model 3676) using the same assay buffer as the 
radiometric assay. Inhibitors and activators were prepared as 
described for the radiometric assays. Assays were performed 
as follows: 2.5 μL of the inhibitor or activator working stock 
was added to a 5 μL solution of kinase and substrate, fol-
lowed by 2.5 μL of ATP to start the assay. All assays were 
performed in quadruplicate. The final concentration of Z’-
LYTE™ S/T23 peptide substrate in the reaction was 2 μM. 
AMPK 111 was used at 79 ng/mL (0.42 nM) in the inhibi-
tion experiments and 41 ng/mL (0.22 nM) in the activation 
experiments, at an ATP concentration of 50 μM. AMPK 
211 was used at 177 ng/mL (0.92 nM) in the inhibition 
experiments and 41 ng/mL (0.22 nM) in the activation ex-
periments, at an ATP concentration of 150 μM. After one 
hour, 5 μL of protease solution was added to a final well 
volume of 15 μL. After a 1 hour incubation at room tempera-
ture the assay plate was read on a Tecan Safire plate reader 
using an excitation wavelength of 400 nm (12 nm bandpass), 
and emission wavelengths of 445 nm (12 nm bandpass) and 
520 nm (12 nm bandpass). The FRET ratio was calculated as 
the intensity of the donor signal divided by the intensity of 
the acceptor signal. The extent of substrate phosphorylation 
was calculated from the FRET ratio as described previously 
[25]. 
Chelation Enhanced Fluorescence (CHEF)-Based Activ-
ity Assays 
  Kinase reactions were performed in a 50 μL reaction 
volume at 30°C in 96-well half-area plate (Corning Model 
3992) using the same assay buffer as the radiometric assays. 
Inhibitors and activators were prepared as described for the 
radiometric assays. Assays were performed by mixing 10 μL 
enzyme solution, 10 μL of substrate peptide solution, 10 μL 
of AMP solution (or H2O for the activator experiments), and 
10 μL of inhibitor or activator solution. The reactions were 
initiated by adding 10 μL of ATP solution. The final concen-
tration of Omnia™ S/T23 peptide substrate in the reaction 
was 8 μM. AMPK 111 was used at 320 ng/mL (1.7 nM), 
at an ATP concentration of 40 μM. AMPK 211 was used 
at 640 ng/mL (3.4 nM), at an ATP concentration of 120 μM. 
The concentration of AMP in the inhibitor titrations was 80 
μM. Immediately after addition of ATP the assay plate was 
placed into a fluorescence plate reader (Molecular Devices 
SpectraMax M5, pre-warmed to 30°C). The plates were read 
for 60 minutes using an excitation wavelength of 360 nm and 
emission wavelength of 485 nm. The reaction rates were 
calculated as the change in fluorescence intensity over time 
(Rfu/sec) over the period where the assay response was lin-
ear. 
Data Analysis 
  Data analysis and curve-fitting was performed using 
GraphPad Prism software (GraphPad Software, Inc, San Di-
ego CA). Curves were fit using a 4-parameter non-linear 
regression, with the “top” of the curve set to a fixed value 
such that datapoints prior to a decrease in AMPK activity 
(due to competition at the ATP site) showed minimal devia-
tion from the calculated curve. 
RESULTS AND DISCUSSION  
Expression and Purification of Recombinant Human 
AMPK 111 and 211 from Insect Cells 
  Structural studies of the heterotrimer have demonstrated 
that the  and  subunits interact with one another via their 
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acts with the  subunit, but the  subunit contact points are 
more centrally located [28, 29]. The former observation sug-
gested that attaching large purification tags (e.g. GST) to the 
 and  C-termini could be contraindicated. The latter ob-
servation was taken as an indication that a small tag (e.g. 6x 
His) would be prudent irrespective of the tag location. In-
deed, various permutations of tagged subunits were tested, 
and those discussed here were the only combinations that 
gave enzymatically active heterotrimeric protein (data not 
shown). 
  Both AMPK isoforms could be purified to approximately 
80% purity as assessed by SDS-PAGE by a single purifica-
tion step on GSH-sepharose, and further purification by siz-
ing column yielded material that was > 85% pure by SDS-
PAGE analysis. Purified recombinant AMPK ran as a single 
distinct band by native PAGE analysis, indicating that all 
three AMPK subunits expressed in insect cells form a stable 
heterotrimeric complex (Fig. 2). In contrast to trimeric 
AMPK expressed in E coli, which showed no detectable ac-
tivity until activated by an upstream kinase [30], trimeric 
AMPK expressed and purified from insect cells showed 
measurable activity that could be increased 5- to 6- fold with 
CAMKK1 (Fig. 3). Both 111 and 211 isoforms were 
activated to a similar level of activity using either CAMKK1 
or LKB1/STRAD/MO25 (data not shown). 
ATP Km Determination 
 ATP  Km determinations were performed for both AMPK 
isoforms in the radiometric assay format using saturating 
concentrations of SAMS substrate in the presence or absence 
of 100 μM AMP (Fig. 4). The 111 isoform showed an 
ATP Km of 34 μM in the absence of AMP, and 74 μM in the 
presence of AMP (Table 1). The 211 isoform showed 
similar values of 65 μM and 73 μM in the absence or pres-
ence of AMP, respectively. These values are similar to those 
previously reported for purified rat liver AMPK, which were 
86 μM or 70 μM in the absence or presence of AMP, respec-
tively [31], and were on the order of the apparent ATP Km 
values determined in the fluorescent assay formats (Table 1).  
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Activation of AMPK 111 () and AMPK 211 () by 
CAMKK1. Activity of AMPK was determined after a 2 hour incu-
bation with CAMKK1 at room temperature. 
Comparison of Small-Molecule Modulators on AMPK 
111 and 211 Activity 
  Compound C was originally described as the first “spe-
cific” inhibitor of AMPK [16], but has recently been shown 
to inhibit a range of other kinases [32, 33]. In our hands, 
compound C showed a slight (< 3-fold) specificity towards 
the 211 isoform in all assay formats tested (Table 1), with 
 
 
 
 
 
 
 
Fig. (4). Radiometric assay of AMPK 111 and 211 in the presence or absence of AMP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). SDS-PAGE and native gel analysis of AMPK 111 and 
211. Lanes 1 and 7: native (non-denaturing) PAGE samples. 
Lanes 2 and 8: Invitrogen Benchmark protein ladder. Lanes 3 – 6: 
AMPK 111 loaded at 1, 2, 5, or 10 μg / lane. Lanes 9 – 12: 
AMPK 211 loaded at 1, 2, 5, or 10 μg / lane. The GST-tagged 
1 and 2 subunits have calculated molecular weights of 90.8 and 
91.4 kDa, respectively. The GST-tagged 1 and 6-His-tagged 1 
subunits have calculated molecular weights of 57.8 and 41.7 kDa, 
respectively. 
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IC50 values on the order of the previously reported 109 nM 
against rat liver AMPK [16], as well as the slightly higher 
value shown in other studies [34].  
  AMPK activation experiments were performed using 
AMP and a panel of three AMP analogs that were chosen 
based on previous literature reports. The bulk of the AMP 
analogs tested caused a compound-dependent increase in 
AMPK activity that reached a maximal value before causing 
a decrease in activity (Fig. 5). This decrease in activity is due 
to competition of the AMP analog for the ATP binding site, 
such as has been observed by others [17, 35]. When the acti-
vation assays were repeated in the FRET-based assay using 
higher concentrations of ATP, the point at which activity 
began to decrease was shifted to higher concentrations of 
activator, consistent with competition of the AMP analogs 
for ATP at the ATP binding site (data not shown). 
  ATMP, a thiophosphate analog of AMP, was the most 
potent activator tested in all assay formats, with a half-
maximal stimulatory concentration of less than 1 μM (Fig. 5 
and Table 1). It also began to inhibit AMPK at a concentra-
tion lower than that observed for the other AMP analogs, 
inhibiting kinase activity at concentrations above 10 – 100 
μM in all formats. When comparing between the two AMPK 
isoforms, the 211 isoform showed half-maximal stimula-
tion at activator concentrations 3 to 6-fold lower than seen 
for the 111 isoform in all assay formats, and comparing 
between the assay formats for each AMPK isoform, the TR-
FRET or CHEF-based assay showed the lowest EC50 values, 
approximately 3- fold lower than the radiometric assay. In 
addition to being more sensitive to stimulation by ATMP, 
the  211 isoform also showed an approximately 2-fold 
greater degree of stimulation than the 111 isoform. In the 
radiometric assay, ATMP stimulated the 111 isoform 1.7-
fold and the 211 isoform 2.9-fold, comparable to that seen 
in the CHEF-based format (1.8- and 2.5-fold for the 111 
and 211 forms, respectively). A greater degree of stimula-
tion for both AMPK isoforms was observed in the FRET-
based assay, where ATMP stimulated the 111 isoform 3.3-
fold and the 211 isoform 6.3-fold. Overall, these results 
compare with those previously reported, in which ATMP 
stimulated partially purified human AMPK 2.5-fold, and 
partially purified rat AMPK 3-fold, with a half-maximal 
stimulatory concentration of 0.65 μM observed for rat 
AMPK, which then inhibited activity above 25 μM [35]. 
  The physiological activator AMP was the next most po-
tent activator of each AMPK isoform, with half-maximal 
stimulation occurring at low- to sub-μM concentrations. As 
with ATMP, there was a slight preference in sensitivity 
(EC50) towards activation of the 211 isoform, ranging 
from 1.1-fold in the radiometric format to 4-fold in the TR-
FRET format. Additionally and as with ATMP, the extent to 
which activity could be increased was greatest for the 211 
isoform, ranging from 2.5-fold in the radiometric assay to 5-
fold in the FRET-based assay. These results are consistent 
with previous studies comparing activation between the 
111 and 211 complexes in which individual isoforms of 
rat liver AMPK were immunoprecipitated either from rat 
liver [36] or from mammalian cells expressing recombinant 
trimeric rat AMPK [37]. In these previous studies the 111 
isoform was maximally activated between 1.7- and 3-fold by 
AMP, whereas 211 isoform was maximally activated be-
tween 3- and 5.5-fold. However, in these previous studies, 
the half- maximal concentration of AMP required for activa-
tion was 2- to 3- fold lower for the 111 isoform when 
compared to the 211 isoform, which is in contrast to our 
results for the human isoforms in which both isoforms 
showed nearly identical sensitivity (EC50) to AMP in the 
radiometric format, and 4-fold greater sensitivity towards the 
211 isoform in the TR-FRET format. Our AMP activation 
results for the 111 isoform are in good agreement with 
published results using purified recombinant rat 111 
AMPK, which showed a maximal 3.3-fold activation of 
AMPK activity, and a half-maximal stimulation at approxi-
mately 1.5 μM [30]. 
  The general trends for AMPK activation by ZMP mir-
rored those seen for ATMP and AMP, albeit with a lower 
potency than seen for those compounds. Potency was re-
duced over an order of magnitude relative to AMP against 
either isoform and in all assay formats, but the maximal 
stimulation of activity was comparable to that seen with 
ATMP and AMP, also with slightly higher stimulation and 
lower EC50 values seen for the 211 isoform. For either 
Table 1.  Summary Comparison of AMPK Isoform Properties. n.d. = Not Determined, n.a. = Not Applicable 
   ATP Km (μM) Inhibitor      
IC50 (nM)  Activator EC50 (μM) / Max. fold-activation  AMPK 
Isoform 
Assay 
Format  - AMP 
+ AMP 
(100 μM)  Cpd C  AMP  ZMP  APR  ATMP 
111  Radiometric  34  74  230  1.6 / 1.7-fold  165 / 1.5-fold  n.d. / n.a.  0.7 / 1.7-fold 
111  TR-FRET  n.d.  n.d.  700  1.4 / n.a.  74 / n.a.  722 / n.a.  0.25 / n.a. 
111  FRET  35  83  320  2.5 / 2.8-fold  112 / 3.3-fold  n.d. / n.a.  0.35 / 3.3-fold 
111  CHEF  31  25  343  0.6 / 1.8-fold  36 / 1.8-fold  n.d. / n.a.  0.25 / 1.8-fold 
211  Radiometric  65  73  88  1.4 / 2.5-fold  54 / 2.5-fold  194 / 1.9-fold  0.13 / 2.9-fold 
211  TR-FRET  n.d.  n.d.  500  0.35 / n.a.  23 / n.a.  43 / n.a.  0.04 / n.a. 
211  FRET  165  154  140  1.4 / 5-fold  40 / 6.3-fold  n.d. / n.a.  0.10 / 6.3-fold 
211  CHEF  82  55  184  0.23 / 2.5-fold  40 / 2.2-fold  n.d. / n.a.  0.07 / 2.5-fold Fluorescent Assays for Characterizing AMPK  Current Chemical Genomics, 2008, Volume 1    39 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Small-molecule activation of AMPK 111 and 211 as determined in different assay formats. AMP (blue circles), ZMP (black 
circles), ATMP (green circles), APR (red circles). 
isoform, the maximum increase in activity was seen in the 
FRET-based assay format relative to the other formats, with 
the FRET-based assay showing a maximum impact of ZMP 
on activity of about twice that seen in the radiometric format 
for either AMPK isoform. Although we are aware of no 
studies that compare ZMP activation between different 
AMPK isoforms, both the magnitude of the increase in activ-
ity as well as the half maximal stimulatory concentration 
observed are consistent with data for rat-liver AMPK, with 
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2-3 fold simulation and half-maximal stimulation occurring 
between 81 and 164 μM being reported [17, 35].  
  Finally, the phosphoramidate analog of AMP, APR, was 
tested as an AMPK activator. The potency of activation was 
lower than that seen for ZMP in all assay formats except for 
the CHEF-based format, in which ZMP showed a slightly 
lower EC50 value for activation. With APR there was a more 
pronounced overall decrease in kinase activity at higher con-
centrations than was seen for the other activators. Again, 
both potency and extent of activation was greater for the 
211 isoform, with the 111 isoform showing negligible 
activation in any formats before inhibiting kinase activity to 
below basal levels. The maximal extent of activation for the 
211 isoform (approximately 2 to 3 fold) is comparable to 
that reported for partially purified human or rat AMPK 
(2.25-fold and 1.5-fold, respectively). Although it is difficult 
to estimate the half-maximal concentration of APR required 
for stimulation from our data, it appears to be greater than 50 
μM, which is in contrast to the 1.9 μM value reported for rat 
AMPK [35]. 
Comparison of Results Between Assay Formats 
  For the radiometric, FRET, and CHEF-based assay for-
mats, each assay was performed at an ATP concentration at 
or near the apparent ATP Km value as determined in that 
particular format. Because the response of the TR-FRET 
format is not strictly linear with respect to product formation 
(rather, it is dependent on the binding of the phosphopeptide 
product to the antibody), it is difficult to determine a rigor-
ous Km value for ATP in this format, and the concentration 
of ATP used in the assay was chosen to match that of the 
FRET-based assay. 
  As a general trend, activator EC50 values were lowest in 
the CHEF- and TR-FRET formats. The radiometric and 
CHEF-based assays showed maximal fold-activation values 
that were comparable to each other, and approximately 2-
fold lower than in the FRET-based assay (in each case the 
assays were configured such that at maximal activation less 
than 30% of the substrate would be converted to product, 
insuring that substrate depletion would have minimal impact 
on the rate of the reaction). Although the fold-activation was 
not calculated for the TR-FRET assay due to the non-linear 
relationship between the TR-FRET value and the extent of 
substrate phosphorylation, the change in the TR-FRET emis-
sion ratio was approximately 2-fold. 
  The activation data we obtained are consistent with the 
reported mechanisms for AMP activation of AMPK, in 
which AMP causes both an increase in the Vmax of the reac-
tion, as well as a decrease in Km for the peptide substrate [31, 
34, 35]. Additionally, the AMP-dependent changes in both 
Vmax and Km have been shown to differ substantially when 
different peptide substrates are used. For example, in radio-
metric studies using 4 similar AMPK substrates it was ob-
served that the AMP-dependent effect on Vmax ranged from 
2-fold to more than 8-fold, depending on the particular pep-
tide substrate being used in the assay [34]. Moreover, when 
peptide substrate Km values were determined in the presence 
or absence of AMP, a 3-4 fold decrease in peptide Km was 
observed in the presence of AMP when comparing peptide 
substrates derived from either ACC or HMG CoA reductase 
[35]. In our radiometric assay the peptide substrate was used 
at 200 μM, which is above its reported Km value, and the 
CHEF format used peptide substrate at 8 μM. In contrast, the 
substrates used in the FRET- and TR-FRET-based assays 
were used at much lower concentrations, presumably far 
below the peptide Km value. From the Michaelis-Menten 
equation: 
] [
] [ max
S K
S V
v
m +
=  
it is clear that when [S] > Km (as is the case in the radiomet-
ric assay), [S] dominates the denominator, and a decrease in 
Km for the substrate will have little effect on the rate of the 
reaction. In contrast, when [S] < Km, a decrease in Km will 
have a larger effect on the denominator, and a greater effect 
on the rate of the reaction. Thus, in assays to identify AMPK 
activators in which part of the mechanism of activation is a 
decrease in substrate Km, it may be advantageous to format 
the assay using sub-Km concentrations of peptide substrate. 
  The assay formats used in these studies each offer spe-
cific advantages and disadvantages relative to one another, 
and choice of an assay format should depend on the specific 
goals of the studies being performed. Although radiometric 
assays are often criticized due to cost associated with waste 
disposal and regulatory compliance, they typically offer the 
widest range of substrate flexibility, both in terms of se-
quence identity and in the concentration of substrate that can 
be used in the assay. For example, for rigorous studies of 
enzyme mechanism it is often desired to use one of the sub-
strates at a concentration above its Km value. In a radiometric 
assay this is limited only by substrate availability (cost) and 
solubility. In a fluorescence-based assay high concentrations 
of substrate can be impractical due to inner filter effects (of-
ten called “color quenching”) caused by the substrate itself, 
which results in a decrease in assay signal. In a TR-FRET 
format, additional complications are encountered at high 
concentration of substrate due to diffusion-enhanced FRET 
between donor and acceptor fluorophores. In this case, the 
high concentration of acceptor fluorophore leads to a greater 
chance of the acceptor diffusing to within a distance from the 
donor required for efficient FRET during the time that the 
FRET signal is measured (typically several hundred micro-
seconds). The result is an increase in background signal, and 
a decrease in assay window. Although fluorescence-based 
studies may be performed using high concentration of sub-
strate, they often require high dilutions of the reaction prior 
to measurement which complicates experimental setup and 
introduces an additional entry point for errors. 
  An important characteristic of the FRET- and CHEF- 
based assays is that the assay output is linear with respect to 
product formation. This is in contrast to the TR-FRET based 
format, in which assay response is dependant on binding of 
phosphorylated product to a phosphospecific antibody. This 
can make the FRET- and CHEF-based formats preferred for 
mechanistic studies (with the caveats noted above). Addi-
tionally, because the CHEF-based format can be monitored 
in real time, additional information can be readily obtained 
for so-called “slow binding” inhibitors. Although not shown 
here, we observed no lag time (within seconds) for AMP 
activation of AMPK using the CHEF-based assay. 
  The TR-FRET format is ideally suited to high-throughput 
screening of large compound libraries. Because the format is Fluorescent Assays for Characterizing AMPK  Current Chemical Genomics, 2008, Volume 1    41 
“time-resolved”, optical interference from fluorescent or 
precipitated compounds (which scatter light) is largely de-
cayed prior to the measurement of the assay signal (in this 
study, 100 μS after excitation). Like the FRET-based format, 
the ratiometric nature of the measurement also corrects to a 
large extent for compounds that absorb excitation light, or 
for minor variations in well-to-well assay volume. 
  It is interesting to note that all of the AMPK activators 
tested showed inhibition of activity at high concentration due 
to competition for ATP at the enzyme active site. As a con-
sequence, when screening large libraries for AMPK modula-
tors, potent activators could be missed when screening at a 
single compound concentration. Ideally, screens for AMPK 
activators should be performed at multiple concentrations of 
compound (i.e. quantitative HTS or “qHTS” format) so that 
such activity is not overlooked [38].  
CONCLUSIONS 
  Although detailed studies of AMPK activity against op-
timized synthetic peptides have been reported [39], AMPK 
acts on a variety of substrates, both in vitro and in vivo (in 
the liver alone, at least 9 substrates for AMPK have been 
identified) [40]. When assaying highly purified recombinant 
AMPK (in contrast to kinase partially purified from tissues 
or cells), specificity of the peptide substrate for a single 
kinase is less of a concern than when assaying kinase iso-
lated from cell or tissue samples, and substrate choice can be 
made based upon the performance of a particular substrate in 
a given assay format. In this report, we have demonstrated 
the ability of a variety of artificial peptide substrates to effi-
ciently serve as substrates for AMPK, and demonstrated that 
the  211 isoform is more sensitive towards AMP and 
AMP-mimetics than is the 111 isoform, and that it can be 
activated to a greater extent. Additionally, in the course of 
this work we have developed and described in detail the 
preparation of recombinant trimeric AMPK from insect cells. 
Taken together, this work should prove useful in the identifi-
cation of small molecule probes that will facilitate not only a 
better understanding of AMPK, but in the development of 
small molecule therapeutics that target this kinase. 
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